Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Tenofovir better than entecavir for minimizing HCC risk in HBV

23 Jan 2020

Tenofovir disoproxil fumarate (TDF) for hepatitis B virus (HBV) infection suppresses hepatocellular carcinoma (HCC) risk better than entecavir, a new study has found.

Researchers retrospectively assessed 29,350 HBV patients (mean age, 52.9±13.2 years; 63.7 percent male) who had received first-line treatment with either TDF (n=1,309; 4.5 percent) or entecavir (n=28,041; 95.5 percent). Participants were followed for 3.6 years for the determination of the cumulative incidence of HCC.

A total of 1,394 patients developed HCC over the observation period, yielding an incidence rate of 4.7 percent. The 1-, 3-, and 5-year cumulative incidence estimates were 1.2 percent, 4.3 percent and 6.8 percent, respectively. Only eight of the HCC cases occurred in the TDF arm (0.6 percent), while the remaining 1,386 (4.9 percent) had been treated with entecavir.

After propensity score matching, patients who were treated with TDF showed a significantly lower risk of developing HCC than their entecavir counterparts (weighted subdistribution hazard ratio [SHR], 0.39, 95 percent confidence interval [CI], 0.18–0.84; p=0.016). This remained true even when analysis was restricted to noncirrhotic patients (weighted SHR, 0.15, 95 percent CI, 0.03–0.74; p=0.02).

The 1-, 3-, and 5-year cumulative incidence rates of HCC in entecavir- vs TDF-treated patients were 0.4 percent vs 0.1 percent, 1.3 percent vs 0.7 percent, and 2.2 percent vs 1.2 percent, respectively.

The present findings warrant further validation in other populations, said researchers. “Future prospective studies would also be valuable to confirm our observations.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.